FRA
MRVI icon

Frank Rimerman Advisors’s Maravai LifeSciences MRVI Stock Holding History

Frank Rimerman Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,593
Closed -$57.7K – 541
2024
Q4 		$57.7K Sell
10,593
-44,462
-81% -$286K ﹤0.01% 516
2024
Q3 		$458K Sell
55,055
-613
-1% -$5.3K 0.03% 343
2024
Q2 		$399K Buy
+55,668
New +$481K 0.03% 388

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Frank Rimerman Advisors's MRVI Position: Q1 2025 in Review

Frank Rimerman Advisors sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 10,593 shares — an estimated $57.7K sold.

Frank Rimerman Advisors first reported a position in MRVI in Q2 2024 and held it in 3 quarters. The position peaked at $458K in Q3 2024. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

  • Frank Rimerman Advisors reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
  • Frank Rimerman Advisors sold 10,593 Maravai LifeSciences shares in Q1 2025, an estimated $57.7K.
  • Frank Rimerman Advisors first reported a position in Maravai LifeSciences in Q2 2024 and held it in 3 quarters.
  • Frank Rimerman Advisors's Maravai LifeSciences position peaked at $458K in Q3 2024.
  • 184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Frank Rimerman Advisors's 13F filing for Q1 2025, filed 12 May 2025.